Jubiglim M 4mg/500mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 4mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, enhancing glucose uptake and utilization. The synergistic action of these two agents provides effective glycemic control by targeting multiple pathophysiological defects of type 2 diabetes. Jubiglim M is prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or lifestyle modification alone. It is essential to monitor blood glucose levels regularly to adjust therapy and minimize the risk of hypoglycemia, particularly due to Glimepiride. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to lactic acidosis, a rare but serious adverse effect associated with Metformin. Common side effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Patient adherence to prescribed dosage and lifestyle modifications is critical for optimal therapeutic outcomes. Jubiglim M should be used under medical supervision with periodic assessment of renal function and glycemic status.